ADIPOQ and hyperhomocysteinemia: Numerous epidemiological and experimental studies have shown that patients with metabolic risk factors such as dyslipidemia, type 2 diabetes mellitus (T2DM), and homocysteinemia are more likely to develop AD, while much less is known about the role of adipokines, such as adiponectin (ADPN), in this regard (5–7).